Changes of Gut-Microbiota-Liver Axis in Hepatitis C Virus Infection

Overview

Journal Biology (Basel)

Publisher MDPI

Specialty Biology

Date 2021 Jan 16

PMID 33451143

Citations 15

Authors

Mohammed El-Mowafy

Abdelaziz Elgaml

Mohamed El-Mesery

Salma Sultan

Tamer A E Ahmed

Ahmed I Gomaa

Mahmoud Aly

Walid Mottawea

Affiliations

Soon will be listed here.

Abstract

The gut-liver-axis is a bidirectional coordination between the gut, including microbial residents, the gut microbiota, from one side and the liver on the other side. Any disturbance in this crosstalk may lead to a disease status that impacts the functionality of both the gut and the liver. A major cause of liver disorders is hepatitis C virus (HCV) infection that has been illustrated to be associated with gut microbiota dysbiosis at different stages of the disease progression. This dysbiosis may start a cycle of inflammation and metabolic disturbance that impacts the gut and liver health and contributes to the disease progression. This review discusses the latest literature addressing this interplay between the gut microbiota and the liver in HCV infection from both directions. Additionally, we highlight the contribution of gut microbiota to the metabolism of antivirals used in HCV treatment regimens and the impact of these medications on the microbiota composition. This review shed light on the potential of the gut microbiota manipulation as an alternative therapeutic approach to control the liver complications post HCV infection.

Citing Articles

Dysregulation in the microbiota by HBV and HCV infection induces an altered cytokine profile in the pathobiome of infection.

Padilha M, Melo F, Laurentino R, da Silva A, Feitosa R Braz J Infect Dis. 2024; 29(1):104468.

PMID: 39608222 PMC: 11636304. DOI: 10.1016/j.bjid.2024.104468.

Insights of gut-liver axis in hepatic diseases: Mechanisms, clinical implications, and therapeutic potentials.

Jeyaraman N, Jeyaraman M, Mariappan T, Muthu S, Ramasubramanian S, Sharma S World J Gastrointest Pharmacol Ther. 2024; 15(6):98146.

PMID: 39534519 PMC: 11551618. DOI: 10.4292/wjgpt.v15.i6.98146.

Jian Gan powder ameliorates immunological liver injury in mice by modulating the gut microbiota and metabolic profiles.

Li K, Cui Y, Zheng X, Min C, Zhang J, Yan Z Eur J Med Res. 2024; 29(1):240.

PMID: 38641655 PMC: 11031866. DOI: 10.1186/s40001-024-01827-2.

Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis.

Maslennikov R, Poluektova E, Zolnikova O, Sedova A, Kurbatova A, Shulpekova Y Int J Mol Sci. 2023; 24(22).

PMID: 38003692 PMC: 10671141. DOI: 10.3390/ijms242216502.

The Role of Gut Dysbiosis in the Loss of Intestinal Immune Cell Functions and Viral Pathogenesis.

Fakharian F, Thirugnanam S, Welsh D, Kim W, Rappaport J, Bittinger K Microorganisms. 2023; 11(7).

PMID: 37513022 PMC: 10384393. DOI: 10.3390/microorganisms11071849.

References

Wang L, Wan Y . The role of gut microbiota in liver disease development and treatment. Liver Res. 2020; 3(1):3-18. PMC: 7251939. DOI: 10.1016/j.livres.2019.02.001. View

Schuppan D, Afdhal N . Liver cirrhosis. Lancet. 2008; 371(9615):838-51. PMC: 2271178. DOI: 10.1016/S0140-6736(08)60383-9. View

Kohara M, Tanaka T, Tsukiyama-Kohara K, Tanaka S, Mizokami M, Lau J . Hepatitis C virus genotypes 1 and 2 respond to interferon-alpha with different virologic kinetics. J Infect Dis. 1995; 172(4):934-8. DOI: 10.1093/infdis/172.4.934. View

Zein N . Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev. 2001; 13(2):223-35. PMC: 100152. DOI: 10.1128/CMR.13.2.223. View

Lu H, Wu Z, Xu W, Yang J, Chen Y, Li L . Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients. Microb Ecol. 2011; 61(3):693-703. DOI: 10.1007/s00248-010-9801-8. View

Andreo U, Maillard P, Kalinina O, Walic M, Meurs E, Martinot M . Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection. Cell Microbiol. 2007; 9(10):2445-56. DOI: 10.1111/j.1462-5822.2007.00972.x. View

Cosseau C, Devine D, Dullaghan E, Gardy J, Chikatamarla A, Gellatly S . The commensal Streptococcus salivarius K12 downregulates the innate immune responses of human epithelial cells and promotes host-microbe homeostasis. Infect Immun. 2008; 76(9):4163-75. PMC: 2519405. DOI: 10.1128/IAI.00188-08. View

Bechmann L, Hannivoort R, Gerken G, Hotamisligil G, Trauner M, Canbay A . The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol. 2011; 56(4):952-64. DOI: 10.1016/j.jhep.2011.08.025. View

Basyte-Bacevice V, Kupcinskas J . Evolution and Revolution of Hepatitis C Management: From Non-A, Non-B Hepatitis Toward Global Elimination. Dig Dis. 2020; :1-6. DOI: 10.1159/000505434. View

10.

Nakano H, Wu S, Sakao K, Hara T, He J, Garcia S . Bilberry Anthocyanins Ameliorate NAFLD by Improving Dyslipidemia and Gut Microbiome Dysbiosis. Nutrients. 2020; 12(11). PMC: 7690841. DOI: 10.3390/nu12113252. View

11.

Sougleri M, Labropoulou-Karatza C, Paraskevopoulou P, Fragopanagou H, Alexandrides T . Chronic hepatitis C virus infection without cirrhosis induces insulin resistance in patients with alpha-thalassaemia major. Eur J Gastroenterol Hepatol. 2001; 13(10):1195-9. DOI: 10.1097/00042737-200110000-00012. View

12.

Simmonds P . Genetic diversity and evolution of hepatitis C virus--15 years on. J Gen Virol. 2004; 85(Pt 11):3173-3188. DOI: 10.1099/vir.0.80401-0. View

13.

Wellhoner F, Doscher N, Tergast T, Vital M, Plumeier I, Kahl S . The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients. Scand J Gastroenterol. 2019; 54(8):1033-1041. DOI: 10.1080/00365521.2019.1647280. View

14.

Simmonds P . The origin of hepatitis C virus. Curr Top Microbiol Immunol. 2013; 369:1-15. DOI: 10.1007/978-3-642-27340-7_1. View

15.

Hill D, Hoffmann C, Abt M, Du Y, Kobuley D, Kirn T . Metagenomic analyses reveal antibiotic-induced temporal and spatial changes in intestinal microbiota with associated alterations in immune cell homeostasis. Mucosal Immunol. 2009; 3(2):148-58. PMC: 2824244. DOI: 10.1038/mi.2009.132. View

16.

Stern J, Miller G, Li X, Saxena D . Virome and bacteriome: two sides of the same coin. Curr Opin Virol. 2019; 37:37-43. PMC: 6768692. DOI: 10.1016/j.coviro.2019.05.007. View

17.

Stauber R, Fauler G, Rainer F, Leber B, Posch A, Streit A . Anti-HCV treatment with ombitasvir/paritaprevir/ritonavir ± dasabuvir is associated with increased bile acid levels and pruritus. Wien Klin Wochenschr. 2017; 129(21-22):848-851. DOI: 10.1007/s00508-017-1268-x. View

18.

Marlicz W, Wunsch E, Mydlowska M, Milkiewicz M, Serwin K, Mularczyk M . The effect of short term treatment with probiotic VSL#3 on various clinical and biochemical parameters in patients with liver cirrhosis. J Physiol Pharmacol. 2017; 67(6):867-877. View

19.

Konturek P, Harsch I, Konturek K, Schink M, Konturek T, Neurath M . Gut⁻Liver Axis: How Do Gut Bacteria Influence the Liver?. Med Sci (Basel). 2018; 6(3). PMC: 6165386. DOI: 10.3390/medsci6030079. View

20.

Canny G, McCormick B . Bacteria in the intestine, helpful residents or enemies from within?. Infect Immun. 2008; 76(8):3360-73. PMC: 2493210. DOI: 10.1128/IAI.00187-08. View